SEARCH

SEARCH BY CITATION

References

  • Anderson, J.E., Kopecky, K.J., Willman, C.L., Head, D., O'Donnell, M.R., Luthardt, F.W., Norwood, T.H., Chen, I.-M., Balcerzak, S.P., Johnson, D.B., Appelbaum, F.R. (2002) Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood, 100, 38693876.
  • Appelbaum, F.R., Gundacker, H., Head, D.R., Slovak, M.L., Willman, C.L., Godwin, J.E., Anderson, J.E., and Petersdorf, S.H. (2006) Age and acute myeloid leukemia. Blood, 107, 34813485.
  • Byrd, J.C., Dodge, R.K., Carroll, A., Baer, M.R., Edwards, C., Stamberg, J., Qumsiyeh, M., Moore, J.O., Mayer, R.J., Davey, F., Schiffer, C.A., Bloomfield, C.D. (1999) Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. Journal of Clinical Oncology, 17, 37673775.
  • Byrd, J.C., Mrozek, K., Dodge, R.K., Carroll, A.J., Edwards, C.G., Arthur, D.C., Pettenati, M.J., Patil, S.R., Rao, K.W., Watson, M.S., Koduru, P.R., Moore, J.O., Stone, R.M., Mayer, R.J., Feldman, E.J., Davey, F.R., Schiffer, C.A., Larson, R.A., Bloomfield, C.D., Cancer and Leukemia Group (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 100, 43254336.
  • Byrd, J.C., Ruppert, A.S., Mrozek, K., Carroll, A.J., Edwards, C.G., Arthur, D.C., Pettenati, M.J., Stamberg, J., Koduru, P.R., Moore, J.O., Mayer, R.J., Davey, F.R., Larson, R.A., Bloomfield, C.D. (2004) Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. Journal of Clinical Oncology, 22, 10871094.
  • Cairoli, R., Beghini, A., Grillo, G., Nadali, G., Elice, F., Ripamonti, C.B., Colapietro, P., Nichelatti, M., Pezzetti, L., Lunghi, M., Cuneo, A., Viola, A., Ferrara, F., Lazzarino, M., Rodeghiero, F., Pizzolo, G., Larizza, L., Morra, E. (2006) Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood, 107, 34633468.
  • Care, R.S., Valk, P.J., Goodeve, A.C., Abu-Duhier, F.M., Geertsma-Kleinekoort, W.M., Wilson, G.A., Gari, M.A., Peake, I.R., Lowenberg, B., Reilly, J.T. (2003) Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. British Journal of Haematology, 121, 13652141.
  • Cassileth, P.A., Andersen, J., Lazarus, H.M., Colvin, O.M., Bennett, J.M., Stadtmauer, E.A., Kaizer, H., Weiner, R.S., Edelstein, M., Oken, M.M. (1993) Autologous bone marrow transplant in acute myeloid leukemia in first remission. Journal of Clinical Oncology, 11, 314319.
  • Cassileth, P.A., Harrington, D.P., Appelbaum, F.R., Lazarus, H.M., Rowe, J.M., Paietta, E., Willman, C., Hurd, D.D., Bennett, J.M., Blume, K.G., Head, D.R., Wiernik, P.H. (1998) Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. New England Journal of Medicine, 339, 16491656.
  • Cassileth, P.A., Lee, S.J., Litzow, M.R., Miller, K.B., Stadtmauer, E.A., Tallman, M.S., Lazarus, H.M., Bennett, J.M., Paietta, E., Dewald, G.W., Rowe, J.M., Eastern COG (2005) Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995). Leukemia & Lymphoma, 46, 5561.
  • Cripe, L.D., Neuberg, D., Tallman, M.S., Litzow, M.R., O'Brien, T.E., Bedrosian, C., Paietta, E., Bennett, J., and Rowe, J. (2000) A phase II trial of subcutaneous recombinant human interleukin 11 (rhIL-11) with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997. Blood, 96, (Part 1), 323a, no. 1393.
  • Delaunay, J., Vey, N., Leblanc, T., Fenaux, P., Rigal-Huguet, F., Witz, F., Lamy, T., Auvrignon, A., Blaise, D., Pigneux, A., Mugneret, F., Bastard, C., Dastugue, N., Van den, A.J., Fiere, D., Reiffers, J., Castaigne, S., Leverger, G., Harousseau, J.L., Dombret, H. French Acute Myeloid Leukemia Intergroup, Groupe Ouest-Est des Leucemies Aigues Myeoblastiques, Leucemies Aigues Myeoblastiques de l'Enfant, Acute Leukemia French Association, Bordeaux-Grenoble-Marseille-Toulouse cooperative group (2003) Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup (Review). Blood, 102, 462469.
  • Downing, J.R. (2003) The core-binding factor leukemias: lessons learned from murine models (Review). Current Opinion in Genetics and Development, 13, 4854.
  • Estey, E.H., Thall, P.F., Cortes, J.E., Giles, F.J., O'Brien, S., Pierce, S.A., Wang, X., Kantarjian, H.M., Beran, M. (2001) Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood, 98, 35753583.
  • Godwin, J.E., Kopecky, K.J., Head, D.R., Willman, C.L., Leith, C.P., Hynes, H.E., Balcerzak, S.P., Appelbaum, F.R. (1998) A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031). Blood, 91, 36073615.
  • Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 92, 23222333.
  • Licht, J.D. (2001) AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML (Review). Oncogene, 20, 56605679.
  • List, A.F., Kopecky, K.J., Willman, C.L., Head, D.R., Persons, D.L., Slovak, M.L., Dorr, R., Karanes, C., Hynes, H.E., Doroshow, J.H., Shurafa, M., Appelbaum, F.R. (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood, 98, 32123220.
  • Liu, P., Tarle, S.A., Hajra, A., Claxton, D.F., Marlton, P., Freedman, M., Siciliano, M.J., Collins, F.S. (1993) Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science, 261, 10411044.
  • Marcucci, G., Mrózek, K., Ruppert, A.S., Maharry, K., Kolitz, J.E., Moore, J.O., Mayer, R.J., Pettenati, M.J., Powell, B.L., Edwards, C.G., Sterling, L.J., Vardiman, J.W., Schiffer, C.A., Carroll, A.J., Larson, R.A., Bloomfield, C.D. (2005) Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 23, 57055717.
  • Nguyen, S., Leblanc, T., Fenaux, P., Witz, F., Blaise, D., Pigneux, A., Thomas, X., Rigal-Huguet, F., Lioure, B., Auvrignon, A., Fiere, D., Reiffers, J., Castaigne, S., Leverger, G., Harousseau, J.L., Socie, G., Dombret, H. (2002) A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood, 99, 35173523.
  • Peniket, A., Wainscoat, J., Side, L., Daly, S., Kusec, R., Buck, G., Wheatley, K., Walker, H., Chatters, S., Harrison, C., Boultwood, J., Goldstone, A., Burnett, A. (2005) Del (9q) AML: clinical and cytological characteristics and prognostic implications. British Journal of Haematology, 129, 210220.
  • Rege, K., Swansbury, G.J., Atra, A.A., Horton, C., Min, T., Dainton, M.G., Matutes, E., Durosinmi, M., Treleaven, J.G., Powles, R.L., Catovsky, D. (2000) Disease features in acute myeloid leukemia with t(8;21)(q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leukemia & Lymphoma, 40, 6777.
  • Rowe, J.M., Andersen, J.W., Mazza, J.J., Bennett, J.M., Paietta, E., Hayes, F.A., Oette, D., Cassileth, P.A., Stadtmauer, E.A., Wiernik, P.H. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood, 86, 457462.
  • Rowe, J.M., Neuberg, D., Friedenberg, W., Bennett, J.M., Paietta, E., Makary, A.Z., Liesveld, J.L., Abboud, C.N., Dewald, G., Hayes, F.A., Tallman, M.S., Wiernik, P.H., Eastern CO (2004) A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood, 103, 479485.
  • Schlenk, R.F., Benner, A., Krauter, J., Buchner, T., Sauerland, C., Ehninger, G., Schaich, M., Mohr, B., Niederwieser, D., Krahl, R., Pasold, R., Dohner, K., Ganser, A., Dohner, H., Heil, G. (2004) Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. Journal of Clinical Oncology, 22, 37413750.
  • Schnittger, S., Kohl, T.M., Haferlach, T., Kern, W., Hiddemann, W., Spiekermann, K., Schoch, C. (2006) KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood, 107, 17911799.
  • Schoch, C., Haase, D., Haferlach, T., Gudat, H., Buchner, T., Freund, M., Link, H., Lengfelder, E., Wandt, H., Sauerland, M.C., Loffler, H., Fonatsch, C. (1996) Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia, 10, 12881295.
  • Schoch, C., Kern, W., Buchner, T., Hiddemann, W., Haferlach, T. (2004) The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Hematologica, 89, 10821090.
  • Slovak, M.L., Kopecky, K.J., Cassileth, P.A., Harrington, D.H., Theil, K.S., Mohamed, A., Paietta, E., Willman, C.L., Head, D.R., Rowe, J.M., Forman, S.J., Appelbaum, F.R. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood, 96, 40754083.
  • Speck, N.A., Gilliland, D.G. (2002) Core-binding factors in haematopoiesis and leukaemia (Review). Nature Reviews Cancer, 2, 502513.
  • Weick, J.K., Kopecky, K.J., Appelbaum, F.R., Head, D.R., Kingsbury, L.L., Balcerzak, S.P., Bickers, J.N., Hynes, H.E., Welborn, J.L., Simon, S.R., Grever, M. (1996) A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study. Blood, 88, 28412851.